Lung Cancer Drug Discoveries: What the future holds 2009: Chapter

Published by: Espicom Healthcare Intelligence

Published: Mar. 17, 2009 - 206 Pages

Table of Contents

EXECUTIVE SUMMARY

The Facts

WHAT IS NSCLC AND HOW DOES IT AFFECT PATIENTS?

PATIENT STATISTICS

Incidence, Diagnosis Rates and Treatment; Now and in the Future

The US

Europe

Japan

Patient Model

The Addressable NSCLC Market Will Increase by 9.8 per cent by 2014

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

THE NSCLC MARKET

GLOBAL NSCLC SALES SPLIT

US Market

European Market

Japanese Market

THE PLAYERS

Players and Products in 2007

Players and Products in 2014

Curent Treatments

SURGERY

RADIATION

CHEMOTHERAPY

Leading Brands

Chemotherapy Regimens

Current Products' Patent Exposure

Novel Targeted Therapies

Targeting EGFr

Targeting VEGF

Current Products' Patent Exposure

ANALYSIS OF LEADING BRANDS

CHEMOTHERAPY

Taxanes

Taxol

Taxotere

Antimetabolites

Alimta

Gemzar

NOVEL TARGETED THERAPIES

EGFr Inhibitors

Iressa

Tarceva

VEGF Inhibitor

Avastin

Sales Forecasts Of Curent Nsc lc Drugs

RESEARCH & DEVELO PMENT OF NSCLC DRUGS

ANALYSIS OF LATE-PHASE DRUGS

CHEMOTHERAPY

Taxanes

Abraxane

Opaxio

TARGETED THERAPY

EGFr Inhibitors

Erbitux

IGF-1r Inhibitors

Figitumumab

Multi-action Inhibitors

Aflibercept

Nexavar

Sutent

Tovok

Vargatef

Zactima

Tumour Vascular Disrupting Agents

ASA404

VACCINES

Lucanix

MAGE-A3

Stimuvax

Other Phase III Drugs

AMG 706

NOV-002

Telcyta

GLOBAL SALES FORECASTS OF LATE-PHASE NSCLC DRUGS

Model Assumptions

ANALYSIS OF PHASE II DRUGS

Chemotherapy

Eloxatin

Ixempra

Satraplatin

Angiogenesis Inhibitors

Recentin

Armala

ABT-869

Axitinib

IMC-1121B

Death Receptor Agonists

AMG 655

AMG 951

Apomab

Mapatumumab

Other Classes

Bavituximab

Enzastaurin

OGX-011

Perifosine

PF-3512676

Velcade

Vaccines

IDM-2101

TG 4010

Competit or Ratio Ana lysis

Competitor Ratio Analysis Criteria

COMPETITOR RATIO ANALYSIS - PRODUCTS

COMPETITOR RATIO ANALYSIS - COMPANIES

WINNERS & LOSERS

Winners

Losers

DISCONTINUATION OF NSCLC DRUGS

APPENDIX 1: PATIENT MODEL

APPENDIX 2: GLO BAL NSCLC DRUGS SALES

APPENDIX 3: PHASE TRANSITION PROBABILITY

BIBLIOGRAPHY

GLOSSARY

Acronymns

Index of Tables

Stages of NSCLC and Survival Rates

Male and Female Lung Cancer Incidence Rates (Top Five Countries)

Summary of Global NSCLC Patient Population Forecasts in Top Seven Countries (2007E-2014E)

Standard NSCLC Therapy

Platinum-Based Regimens

FDA-Approved Regimens for Advanced NSCLC

Doublet Regimens

EGFr Expression in Solid Tumours

Patent Exposure of Leading Brands

Efficacy of Taxotere in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based Chemotherapy Regimen (Intent-to-Treat Analysis)

Proposed NSCLC Filings for Avastin

Avastin Development

Proposed Filings of New Indications for Avastin

Global NSCLC Sales of Leading Brands 2007A-2014E (US$ millions)

Products In Clinical Development for the Treatment Of NSCLC

New Drugs in Late-Phase Development to Treat NSCLC

Sales Forecasts of Late-Phase Developmental NSCLC Drugs (US$ million)

New Drugs in Phase II Development to Treat NSCLC

Axitinib Treatment-Related Adverse Events

Key NSCLC Drugs Analysed

Summary of Key Companies and Drugs in the NSCLC Market by 2014

NSCLC Drugs Discontinued During Development

Summary of US NSCLC Patient Population Forecasts

Summary of Europe (Top Five) NSCLC Patient Population Forecasts

Summary of Japan NSCLC Patient Population Forecasts

Global NSCLC Drugs Sales 2007A-2014E

Probability of Launch

Index of Charts

Schematic of the Lung

New Cancer Deaths Estimates (2008)*

Tobacco use in the US 1900-2002

Global NSCLC Market by Therapy Class (2007A)

Global NSCLC Market by Therapy Class (2014E)

Global NSCLC Market by Region (2007A)

US NSCLC Major Drugs Sales Split (2007A)

European NSCLC Major Drugs Sales Split (2007A)

Market Share of NSCLC Players by Sales (2007A)

Market Share of NSCLC Players by Sales (2014E)

EGFr Signal Transduction in Tumour Cells

Angiogenesis is the Formation of New Blood Vessels

Agents Targeting the VEGF Pathway

Efficacy Parameters in Phase III Trials

Taxol NSCLC Sales (2007E-2014E)

TAX317 Survival K_M Curves - Taxotere 75mg/m2 vs. Best Supportive Care

TAX320 Survival K_M Curves - Taxotere 75mg/m2 vs. Vinorelbine or Ifosfamide Control

Taxotere-Treated Patients as % of Patient Popluation (Top 7)

Taxotere NSCLC Sales (2007E-2014E)

Alimta NSCLC Sales (2007A-2014E)

Gemzar NSCLC Sales (2007E-2014E)

Iressa NSCLC Sales (2007A-2014E)

Tarceva NSCLC Sales (2007E-2014E)

Avastin NSCLC Sales (2007E-2014E)

2008 Survey: Medicines in Development for Cancer

Abraxane NSCLC Sales (2011E-2014E)

Opaxio NSCLC Sales (2009E-2014E)

Erbitux NSCLC Sales (2009E-2014E)

Pfizer's NSCLC Clinical Development Programme

CP-751,871 NSCLC Sales (2013E-2014E)

Aflibercept NSCLC Sales (2012E-2014E)

Nexavar NSCLC Sales (2012E-2014E)

Sutent NSCLC Phase II Results and Phase III (SUN 1087) Study Design

Pfizer's NSCLC Clinical Development Programme

Sutent NSCLC Sales (2012E-2014E)

Tovok NSCLC Sales (2013E-2014E)

Vargatef NSCLC Sales (2013E-2014E)

Zactima’s Triple Mechanism of Action

Zactima NSCLC Sales (2010E-2014E)

ASA404 NSCLC Sales (2012E-2014E)

Stimuvax NSCLC Sales (2012E-2014E)

Ixabepilone: Preclinical Synergy With Targeted Therapies

AZD2171 Mechanism Of Action

Efficacy and Pharmacokinetic Profile of AZD2171 Compared to Avastin

AZD2171 Dose-Dependent Efficacy in NSCLC

Axitinib in First-Line NSCLC

Mechanism of Action of HGS-ETR1

PF-3512676 Mechanism of Action Through TLR modulation

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.